All patients
Age < 65y (younger) Age > 65y Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
lung cancer : non small cell (NSCLC), nivolumab based treatment vs. platinum derivate, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.78 [0.60; 1.02]
0.78 [0.60 ; 1.02 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 363 NA not evaluable progression or deaths (PFS)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.73 [0.56; 0.95]
0.73 [0.56 ; 0.95 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 363 NA not evaluable STRAE (any grade)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.75 [1.00; 3.09]
1.75 [1.00 ; 3.09 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.05 [1.12; 3.76]
2.05 [1.12 ; 3.76 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable TRAE (any grade)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 3.42 [1.76; 6.65]
3.42 [1.76 ; 6.65 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.35 [1.53; 3.60]
2.35 [1.53 ; 3.60 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 4.33 [0.48; 39.16]
4.33 [0.48 ; 39.16 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.89 [0.48; 1.63]
0.89 [0.48 ; 1.63 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.80 [0.38; 1.70]
0.80 [0.38 ; 1.70 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.34 [0.75; 2.38]
1.34 [0.75 ; 2.38 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.07; 17.15]
1.06 [0.07 ; 17.15 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.26 [0.01; 5.89]
0.26 [0.01 ; 5.89 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
1.43 [0.32 ; 6.48 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.15; 7.64]
1.06 [0.15 ; 7.64 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.18 [0.65; 7.39]
2.18 [0.65 ; 7.39 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.85 [0.22; 3.21]
0.85 [0.22 ; 3.21 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.19 [0.63; 2.24]
1.19 [0.63 ; 2.24 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.02; 53.93]
1.06 [0.02 ; 53.93 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.13 [0.07; 64.04]
2.13 [0.07 ; 64.04 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
1.43 [0.32 ; 6.48 ] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1 0% 355 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 00:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 855,360,719,721,720,842,642,674,1085,863